文献速递血栓与止血

皮下艾加莫德PH20治疗成人原发免疫性血小板减少症:ADVANCE SC III期随机双盲安慰剂对照试验

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.
PubMed 文献 · Am J Hematol · 2026-04-06

ADVANCE SC是一项III期多中心随机双盲安慰剂对照研究,评估皮下艾加莫德PH20在成人原发免疫性血小板减少症中的疗效与安全性。207例血小板<30×10^9/L且接受过>1种既往治疗的患者按2:1随机接受1000 mg艾加莫德PH20皮下注射或安慰剂。主要终点(第19-24周6次访视中至少4次血小板≥50×10^9/L)两组差异无统计学意义(-13.7% vs 16.2%,p=0.51),未证实优效性;药物耐受性良好。

要点

  • 皮下艾加莫德PH20未在主要或次要终点上证实优于安慰剂。
  • 主要终点达标率艾加莫德组-13.7%(17/124) vs 安慰剂组16.2%(11/68),p=0.51。
  • 艾加莫德PH20皮下注射耐受性良好,不良事件多为轻中度且组间相当。

核心结论

  • 皮下艾加莫德PH20在成人原发ITP中未证实优于安慰剂的疗效,主要和次要终点均未达到优效性。
  • 艾加莫德PH20皮下注射耐受性良好,多数不良事件为轻中度且与安慰剂组相当。

研究设计与样本

  • III期、多中心、随机、双盲、安慰剂对照、平行组研究(ADVANCE SC)。
  • 207例血小板<30×10^9/L且接受过>1种既往ITP治疗的成人原发ITP患者,按2:1随机接受1000 mg艾加莫德PH20皮下注射(n=137)或安慰剂(n=70)。
  • 给药方案:第1-4次访视每周一次,第5-16次访视根据应答每周或每两周一次,第17-24次访视固定给药间隔。
  • 92.8%(192/207)为慢性ITP,74.9%(155/207)接受过至少3种既往ITP治疗,中位诊断至入组时间7.0年。

主要发现

  • 主要终点(第19-24周6次访视中至少4次血小板≥50×10^9/L)达标率:艾加莫德组-13.7%(17/124) vs 安慰剂组16.2%(11/68),p=0.51,调整后比例差-3.5%(95%CI -14.7-7.0)。
  • 艾加莫德PH20皮下注射耐受性良好,多数不良事件为轻中度且治疗组间相当。
  • 血小板计数较基线的升高幅度在安慰剂组高于预期、在艾加莫德PH20组低于预期。

临床怎么用

  • 本研究未证实皮下艾加莫德PH20在经多线治疗的成人原发ITP中优于安慰剂,不支持据此将其作为该人群的常规选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health-related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study, evaluated the efficacy and safety of subcutaneous efgartigimod PH20 in adults with primary ITP. Participants with platelet counts < 30 × 109/L who received more than one prior ITP therapy. Between December 16, 2020, and October 9, 2023, 207 participants were randomized (2:1) to receive 1000 mg efgartigimod PH20 SC (n = 137) or placebo (n = 70) once weekly (visits 1-4), weekly or biweekly (depending upon response; visits 5-16), and at a fixed dosing interval (visits 17-24). Most (92.8% [192/207]) had chronic ITP and 74.9% (155/207) received at least three previous ITP treatments. The median time since diagnosis was 7.0 years. Superior efficacy of efgartigimod PH20 SC versus placebo was not demonstrated for the primary or secondary endpoints, with a comparable proportion of efgartigimod PH20 SC and placebo-treated participants achieving the primary efficacy endpoint (platelet count ≥ 50 × 109/L for at least four of the six visits during weeks 19-24): -13.7% [17/124] versus 16.2% [11/68], respectively; p = 0.51; adjusted difference in proportions, -3.5% [95% CI, -14.7-7.0]. Efgartigimod PH20 SC was well tolerated: most adverse events were mild to moderate and comparable between treatment groups. Platelet count increases from baseline were higher than expected with placebo and lower than expected with efgartigimod PH20 SC. Clinical Trial Registration: The ADVANCE SC trial is registered on ClinicalTrials.gov (NCT04687072).

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Cooper N, Broome CM, Miyakawa Y, et al. Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial. Am J Hematol. 2026. PMID: 41943179. doi:10.1002/ajh.70303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。